Beyond the 2008 World Health Organization classification: The role of the hematopathology laboratory in the diagnosis and management of acute lymphoblastic leukemia

Seminars in Diagnostic Pathology

Volumn 29, Issue 1, 2012, Pages 2-11

  McGregor, Stephanie ^a   McNeer, Jennifer ^a   Gurbuxani, Sandeep ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Acute lymphoblastic leukemia; ALL prognosis; BCR ABL; IKZF

Indexed keywords

ANTHRACYCLINE; ASPARAGINASE; BCR ABL PROTEIN; CD19 ANTIGEN; CD2 ANTIGEN; CD22 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; CD4 ANTIGEN; CD7 ANTIGEN; CD79A ANTIGEN; CD8 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GLUCOCORTICOID; IMATINIB; NOTCH1 RECEPTOR; T LYMPHOCYTE RECEPTOR DELTA CHAIN; T6 ANTIGEN; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B CELL LEUKEMIA; CANCER CLASSIFICATION; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION 1; CHROMOSOME TRANSLOCATION 12; CHROMOSOME TRANSLOCATION 5; CHROMOSOME TRANSLOCATION 9; CLINICAL FEATURE; DISEASE COURSE; FLOW CYTOMETRY; GENE DELETION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; IMMUNOPHENOTYPING; LEUKOPENIA; MEDICAL DECISION MAKING; MINIMAL RESIDUAL DISEASE; MOLECULAR GENETICS; ONCOGENE; PATIENT CARE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; T CELL LEUKEMIA; WORLD HEALTH ORGANIZATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW CELLS; CLINICAL LABORATORY TECHNIQUES; CYTOGENETIC ANALYSIS; HUMANS; IMMUNOPHENOTYPING; NEOPLASM, RESIDUAL; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TUMOR MARKERS, BIOLOGICAL; WORLD HEALTH ORGANIZATION;

EID: 84856147587     PISSN: 07402570     EISSN: 19301111     Source Type: Journal    
DOI: 10.1053/j.semdp.2011.07.004     Document Type: Article

References (90)

1. Pui C.H., Carroll W.L., Meshinchi S., et al. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011, 29:551-565.
2. Smith M., Arthur D., Camitta B., et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996, 14:18-24.
3. Look A.T., Roberson P.K., Williams D.L., et al. Prognostic importance of blast cell DNA content in childhood acute lymphoblastic leukemia. Blood 1985, 65:1079-1086.
4. Moorman A.V., Ensor H.M., Richards S.M., et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol 2010, 11:429-438.
5. Trueworthy R., Shuster J., Look T., et al. Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study. J Clin Oncol 1992, 10:606-613.
6. Harris M.B., Shuster J.J., Carroll A., et al. Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: a Pediatric Oncology Group study. Blood 1992, 79:3316-3324.
7. Sutcliffe M.J., Shuster J.J., Sather H.N., et al. High concordance from independent studies by the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI Standard-Risk B-precursor Acute Lymphoblastic Leukemia: a Children's Oncology Group (COG) initiative. Leukemia 2005, 19:734-740.
8. Heerema N.A., Sather H.N., Sensel M.G., et al. Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (> 50 chromosomes). J Clin Oncol 2000, 18:1876-1887.
9. Borkhardt A., Cazzaniga G., Viehmann S., et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Study Group. Blood 1997, 90:571-577.
10. McLean T.W., Ringold S., Neuberg D., et al. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood 1996, 88:4252-4258.
11. Rubnitz J.E., Downing J.R., Pui C.H., et al. TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. J Clin Oncol 1997, 15:1150-1157.
12. Borowitz M.J., Devidas M., Hunger S.P., et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 2008, 111:5477-5485.
13. Chessels J.M., Swansbury G.J., Reeves B., et al. Cytogenetics and prognosis in childhood lymphoblastic leukaemia: results of MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia. Br J Haematol 1997, 99:93-100.
14. Nachman J.B., Heerema N.A., Sather H., et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 2007, 110:1112-1115.
15. Harrison C.J., Haas O., Harbott J., et al. Detection of prognostically relevant genetic abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: recommendations from the Biology and Diagnosis Committee of the International Berlin-Frankfürt-Münster study group. Br J Haematol 2010, 151:132-142.
16. Aricò M., Valsecchi M.G., Camitta B., et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000, 342:998-1006.
17. Uckun F.M., Nachman J.B., Sather H.N., et al. Poor treatment outcome of Philadelphia chromosome-positive pediatric acute lymphoblastic leukemia despite intensive chemotherapy. Leuk Lymphoma 1999, 33:101-106.
18. Schultz K.R., Bowman W.P., Aledo A., et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children's Oncology Group study. J Clin Oncol 2009, 27:5175-5181.
19. Crist W.M., Carroll A.J., Shuster J.J., et al. Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): a Pediatric Oncology Group study. Blood 1990, 76:117-122.
20. Raimondi S.C., Behm F.G., Roberson P.K., et al. Cytogenetics of pre-B-cell acute lymphoblastic leukemia with emphasis on prognostic implications of the t(1;19). J Clin Oncol 1990, 8:1380-1388.
21. Felice M.S., Gallego M.S., Alonso C.N., et al. Prognostic impact of t(1;19)/TCF3-PBX1 in childhood acute lymphoblastic leukemia in the context of Berlin-Frankfurt-Münster-based protocols. Leuk Lymphoma 2011, 52:1215-1221.
22. Robinson H.M., Broadfield Z.J., Cheung K.L., et al. Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome. Leukemia 2003, 17:2249-2250.
23. Moorman A.V., Richards S.M., Robinson H.M., et al. Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). Blood 2007, 109:2327-2330.
24. Attarbaschi A., Mann G., Panzer-Grümayer R., et al. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials. J Clin Oncol 2008, 26:3046-3050.
25. Hunger S.P. Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: clinical features and molecular pathogenesis. Blood 1996, 87:1211-1224.
26. Inukai T., Hirose K., Inaba T., et al. Hypercalcemia in childhood acute lymphoblastic leukemia: frequent implication of parathyroid hormone-related peptide and E2A-HLF from translocation 17;19. Leukemia 2007, 21:288-296.
27. Graux C., Cools J., Michaux L., et al. Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast. Leukemia 2006, 20:1496-1510.
28. Bassan R., Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 2011, 29:532-543.
29. Campana D. Minimal residual disease in acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Programs 2010, 2010:7-12.
30. den Boer M.L., van Slegtenhorst M., de Menezes R.X., et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009, 10:125-134.
31. Mullighan C.G., Su X., Zhang J., et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009, 360:470-480.
32. Mullighan C.G., Miller C.B., Radtke I., et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008, 453:110-114.
33. Mullighan C.G., Zhang J., Harvey R.C., et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2009, 106:9414-9418.
34. Mullighan C.G., Collins-Underwood J.R., Phillips L.A.A., et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 2009, 41:1243-1246.
35. Cario G., Zimmermann M., Romey R., et al. Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood 2010, 115:5393-5397.
36. Harvey R.C., Mullighan C.G., Wang X., et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood 2010, 116:4874-4884.
37. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 2008, 22:23-30.
38. Kuiper R.P., Schoenmakers E.F.P.M., van Reijmersdal S.V., et al. High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. Leukemia 2007, 21:1258-1266.
39. Mullighan C.G., Goorha S., Radtke I., et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007, 446:758-764.
40. Iacobucci I., Lonetti A., Paoloni F., et al. The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party. Haematologica 2010, 95:1683-1690.
41. Pullen J., Shuster J.J., Link M., et al. Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group (POG) study. Leukemia 1999, 13:1696-1707.
42. Pui C.H., Behm F.G., Crist W.M. Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 1993, 82:343-362.
43. Uckun F.M., Gaynon P.S., Sensel M.G., et al. Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a Children's Cancer Group study. J Clin Oncol 1997, 15:2214-2221.
44. van Grotel M., Meijerink J.P.P., van Wering E.R., et al. Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. Leukemia 2008, 22:124-131.
45. Cavé H., Suciu S., Preudhomme C., et al. Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951. Blood 2004, 103:442-450.
46. Ferrando A.A., Neuberg D.S., Staunton J., et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002, 1:75-87.
47. Ferrando A.A., Neuberg D.S., Dodge R.K., et al. Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia. Lancet 2004, 363:535-536.
48. Haferlach T., Kohlmann A., Wieczorek L., et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol 2010, 28:2529-2537.
49. Cleaver A.L., Beesley A.H., Firth M.J., et al. Gene-based outcome prediction in multiple cohorts of pediatric T-cell acute lymphoblastic leukemia: a Children's Oncology Group study. Mol Cancer 2010, 9:105.
50. Ellisen L.W., Bird J., West D.C., et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991, 66:649-661.
51. Ma S.K., Wan T.S., Chan L.C. Cytogenetics and molecular genetics of childhood leukemia. Hematol Oncol 1999, 17:91-105.
52. Weng A.P., Ferrando A.A., Lee W., et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004, 306:269-271.
53. Palomero T., Dominguez M., Ferrando A.A. The role of the PTEN/AKT pathway in NOTCH1-induced leukemia. Cell Cycle 2008, 7:965-970.
54. Aifantis I., Vilimas T., Buonamici S. Notches, NFkappaBs and the making of T cell leukemia. Cell Cycle 2007, 6:403-406.
55. Demarest R.M., Ratti F., Capobianco A.J. It's T-ALL about Notch. Oncogene 2008, 27:5082-5091.
56. Palomero T., Sulis M.L., Cortina M., et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 2007, 13:1203-1210.
57. Silva A., Yunes J.A., Cardoso B.A., et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 2008, 118:3762-3774.
58. Asnafi V., Buzyn A., Le Noir S., et al. NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood 2009, 113:3918-3924.
59. Breit S., Stanulla M., Flohr T., et al. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood 2006, 108:1151-1157.
60. Malyukova A., Dohda T., von der Lehr N., et al. The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res 2007, 67:5611-5616.
61. Park M.J., Taki T., Oda M., et al. FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. Br J Haematol 2009, 145:198-206.
62. Baldus C.D., Thibaut J., Goekbuget N., et al. Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia. Haematologica 2009, 94:1383-1390.
63. Zuurbier L., Homminga I., Calvert V., et al. NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. Leukemia 2010, 24:2014-2022.
64. Clappier E., Collette S., Grardel N., et al. NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951. Leukemia 2010, 24:2023-2031.
65. Mansour M.R., Sulis M.L., Duke V., et al. Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. J Clin Oncol 2009, 27:4352-4356.
66. Larson Gedman A., Chen Q., Kugel Desmoulin S., et al. The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leukemia 2009, 23:1417-1425.
67. Palomero T., Ferrando A. Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma 9 suppl 2009, 3:S205-S210.
68. Milano J., McKay J., Dagenais C., et al. Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci 2004, 82:341-358.
69. van Es J.H., van Gijn M.E., Riccio O., et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005, 435:959-963.
70. Wei P., Walls M., Qiu M., et al. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther 2010, 9:1618-1628.
71. Real P.J., Tosello V., Palomero T., et al. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med 2009, 15:50-58.
72. Real P.J., Ferrando A.A. NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia. Leukemia 2009, 23:1374-1377.
73. Coustan-Smith E., Mullighan C.G., Onciu M., et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009, 10:147-156.
74. Gutierrez A., Dahlberg S.E., Neuberg D.S., et al. Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia. J Clin Oncol 2010, 28:3816-3823.
75. Stumpel D.J.P.M., Schneider P., van Roon E.H.J., et al. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options. Blood 2009, 114:5490-5498.
76. Román-Gómez J., Jiménez-Velasco A., Agirre X., et al. CpG island methylator phenotype redefines the prognostic effect of t(12;21) in childhood acute lymphoblastic leukemia. Clin Cancer Res 2006, 12:4845-4850.
77. Román-Gómez J., Jiménez-Velasco A., Agirre X., et al. Lack of CpG island methylator phenotype defines a clinical subtype of T-cell acute lymphoblastic leukemia associated with good prognosis. J Clin Oncol 2005, 23:7043-7049.
78. Román-Gómez J., Jiménez-Velasco A., Castillejo J.A., et al. Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood 2004, 104:2492-2498.
79. Milani L., Lundmark A., Kiialainen A., et al. DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia. Blood 2010, 115:1214-1225.
80. Mullighan C.G., Zhang J., Kasper L.H., et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 2011, 471:235-239.
81. Stumpel D.J.P.M., Schotte D., Lange-Turenhout E.A.M., et al. Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at a micro scale. Leukemia 2011, 25:429-439.
82. Román-Gómez J., Agirre X., Jiménez-Velasco A., et al. Epigenetic regulation of microRNAs in acute lymphoblastic leukemia. J Clin Oncol 2009, 27:1316-1322.
83. Román-Gómez J., Cordeu L., Agirre X., et al. Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. Blood 2007, 109:3462-3469.
84. Ruiz-Magaña M.J., Rodríguez-Vargas J.M., Morales J.C., et al. The DNA-methyltransferase inhibitors zebularine and decitabine induce mitochondria-mediated apoptosis and DNA damage in p53 mutant leukemic T cells. Int J Cancer 2011, epub ahead of print 31 March.
85. Okamoto R., Ogawa S., Nowak D., et al. Genomic profiling of adult acute lymphoblastic leukemia by single nucleotide polymorphism oligonucleotide microarray and comparison to pediatric acute lymphoblastic leukemia. Haematologica 2010, 95:1481-1488.
86. Paulsson K., Cazier J.B., Macdougall F., et al. Microdeletions are a general feature of adult and adolescent acute lymphoblastic leukemia: Unexpected similarities with pediatric disease. Proc Natl Acad Sci U S A 2008, 105:6708-6713.
87. Yoda A., Yoda Y., Chiaretti S., et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2010, 107:252-257.
88. Harvey R.C., Mullighan C.G., Chen I.M., et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 2010, 115:5312-5321.
89. O'Neil J., Grim J., Strack P., et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med 2007, 204:1813-1824.
90. Thompson B.J., Buonamici S., Sulis M.L., et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med 2007, 204:1825-1835.